Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Dzhelil Osmanov"'
Autor:
Marcin Wójtowicz, Gianluigi Reda, Robin Foà, Mehmet Turgut, Eugen Tausch, Sebastian Böttcher, Marlies E.H.M. Van Hoef, Thomas Perretti, Jens Kisro, Francesc Bosch, Osman Ilhan, Sue Robinson, Beatrice Mahe, Veronique Leblond, Dzhelil Osmanov, Eva Mikuskova, Stephan Stilgenbauer, Peter Trask
Publikováno v:
British Journal of Haematology
British Journal of Haematology, Wiley, 2021, ⟨10.1111/bjh.17326⟩
Scientia
British Journal of Haematology, Wiley, 2021, ⟨10.1111/bjh.17326⟩
Scientia
Summary The manageable toxicity profile of obinutuzumab (GA101; G) alone or with chemotherapy in first‐line (1L; fit and non‐fit) and relapsed/refractory (R/R) patients with chronic lymphocytic leukaemia (CLL) was established in the primary analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f36fd119698300a25c003d9a2e6aa91d
Autor:
Carlos Panizo, Jan de Jong, James Jiao, Daniel Patricia, Peter Hellemans, Raul Cordoba, Juthamas Sukbuntherng, Daniele Ouellet, Severijn De Wilde, Vijay Chauhan, Alexander Myasnikov, Loeckie de Zwart, Dzhelil Osmanov, Georgii Manikhas, Jan Snoeys, Tara Masterson
Publikováno v:
Leukemialymphoma. 59(12)
This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recom
Autor:
Judith Trotman, Sally F Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter R Fingerle-Rowson, Jiawen Zhu, Tina Nielsen, Deniz Sahin, Wolfgang Hiddemann, Robert E Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van eygen, Randeep Sangha, Pam Mckay, Jonathan Wilson, Richard Van Der Jagt, Daryl Roitman, Marek Trneny, Jiri Mayer, Katell Le Du, Philippe Solal-Celigny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange-Krex, Axel Florschütz, Hans-Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Hess, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling-Kaiser, Martin Hoffmann, Zita Borbenyi, Miklos Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Angel Canales Albendea, Francisco Javier Peñalver Parraga, Alfonso Soler Campos, Juan Manuel Sancho Cia, Jose Antonio Marquez Navarro, Carlos Grande Garcia, Herman Nilsson-Ehle, Helen Mccarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin Dyer, Ruth Pettengell, John Seymour, John Gribben, Saad Al-Ismail, Faris Al-Refaie, Norbert Blesing, Christopher Macnamara, Ann O'callaghan, Andrew Haynes, George Follows, Roderick Johnson, David Cunningham, Kristian Bowles, Graham Collins, Eve Gallop-Evans, Stephen Robinson, Chezhian Subash, James Bailey, Viran Holden, Jeffrey Neidhart, Moacyr De Oliveira, Haluk Tezcan, Kevin Kim, Suman Kambhampati, Keith Lanier, John Mcclean, Kensei Tobinai, Kiyohiko Hatake, Michinori Ogura, Toshiki Uchida, Kiyoshi Ando, Tomohiro Kinoshita, Thomas Höhler, Heribert Stauder, Andreas Kirsch, Michael Koenigsmann, Stephan Kremers, Thomas Illmer, Mathias Witzens-Harig, Paul La Roseé, Jan Dürig, Michael Kneba, Manfred Hensel, Stefan Fuxius, Lothar Bergmann, Kai Hübel, Christian Buske, Reinhard Marks, Gerald Wulf, Christian Lerchenmueller, Rudolf Schmits, Mark Reinwald, Eva Lengfelder, Fiona Scott, Takaaki Chou, Masafumi Taniwaki, Isao Yoshida, Kenichi Ishizawa, Naokuni Uike, Nobuhiko Uoshima, Yuri Kamitsuji, Shinsuke Iida, Ken Ohmine, Kisato Nosaka, Kazuhiko Ide, Takayuki Ishikawa, Pierre Desjardins, Nicholas Finn, Jun Zhu, Wei Li, Li Yu, Hanyun Ren, Yuan Kai Shi, Gang Wu, Xiaonan Hong, Qingyuan Zhang, Jifeng Feng, Rong Zhan, Tongyu Lin, Sirpa Leppa, Regis Costello, Adrian Tempescul, Laurence Sanhes, Olivier Tournilhac, Heinz Kirchen, Holger Hebart, Rudolf Weide, Kathleen Jentsch-Ullrich, Irit Avivi, Arnon Nagler, Ronit Gurion, Ofer Shpilberg, Pietro Leoni, Luca Baldini, Olga Samoylova, Alexandr Myasnikov, Tran-Der Tan, Hung Chang, Kyoya Kumagai, Norifumi Tsukamoto, Kunihiro Tsukasaki, Patrick Beatty, Noriko Usui, Koji Izutsu, Tohru Murayama, Tatsuo Ichinohe, Kohmei Kubo, Fumihiro Ishida, J. Thaddeus Beck, Frank Griesinger, Dzhelil Osmanov, Shaker Dakhil, Aline Clavert, Dai Maruyama, Yasuhito Terui, Kazuhito Yamamoto, Ekkehard Eigendorff, Tsutomu Kobayashi, Satoshi Ichikawa, Ilseung Choi, Katsuya Wada, Yoshitaka Kikukawa, Masao Matsuoka, Takayuki Yoshino, Yosuke Minami
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2018, 19 (11), pp.1530--1542. ⟨10.1016/S1470-2045(18)30618-1⟩
Trotman, J, Barrington, S F, Belada, D, Meignan, M, MacEwan, R, Owen, C, Ptáčník, V, Rosta, A, Fingerle-Rowson, G R, Zhu, J, Nielsen, T, Sahin, D, Hiddemann, W, Marcus, R E, Davies, A 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
PET investigators from the GALLIUM study 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
Lancet Oncology, Elsevier, 2018, 19 (11), pp.1530--1542. ⟨10.1016/S1470-2045(18)30618-1⟩
Trotman, J, Barrington, S F, Belada, D, Meignan, M, MacEwan, R, Owen, C, Ptáčník, V, Rosta, A, Fingerle-Rowson, G R, Zhu, J, Nielsen, T, Sahin, D, Hiddemann, W, Marcus, R E, Davies, A 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
PET investigators from the GALLIUM study 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary
Autor:
Andy I. Chen, Eric L. Sievers, Patrick J. Stiff, Tamas Masszi, Andy Chi, Dirk Huebner, Jerzy Holowiecki, Angelo Michele Carella, Craig H. Moskowitz, Emily K. Larsen, Dzhelil Osmanov, Edward Agura, Veronika Bachanova, Auayporn Nademanee, Jan Walewski, John W. Sweetenham, Alessandro M. Gianni, Naomi N. H. Hunder, Anna Sureda, Muneer H. Abidi
Publikováno v:
The Lancet. 385:1853-1862
High-dose therapy followed by autologous stem-cell transplantation is standard of care for patients with relapsed or primary refractory Hodgkin's lymphoma. Roughly 50% of patients might be cured after autologous stem-cell transplantation; however, mo
Autor:
Jin Seok Kim, Michinori Ogura, Dzhelil Osmanov, Mariana Vasilica, Christian Buske, Sang Joon Lee, Edvard Zhavrid, Rajinish Nagarkar, Yun Ju Bae, Won Seog Kim, Wojciech Jurczak, Jose Angel Hernandez-Rivas, Sungyoung Lee, Bertrand Coiffier, Aliaksandr Prokharau, Juan-Manuel Sancho, Larry W. Kwak
Publikováno v:
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background Studies in patients with rheumatoid arthritis have shown that the rituximab biosimilar CT-P10 (Celltrion, Incheon, South Korea) has equivalent efficacy and pharmacokinetics to rituximab. In this phase 3 study, we aimed to assess the non-in
Autor:
J. Morton, Andrew Spencer, Stephen J. Schuster, Judith Trotman, John Radford, Michael Schaffer, Peter Martin, Wojciech Jurczak, Dolores Caballero, Nathan Fowler, J. Hou, S. Deshpande, Dzhelil Osmanov, R. Damle, Bruce D. Cheson, Jessica Vermeulen, Sriram Balasubramanian, M. Lill, Ajay K. Gopal, Gilles Salles, Umberto Vitolo, Georg Hess, Abdulraheem Yacoub
Publikováno v:
Hematological Oncology. 35:210-211
Autor:
M. D. Caballero Barrigón, Beth Christian, Catherine Thieblemont, Zafer Gulbas, P. Armand, Arkendu Chatterjee, A. Majlis, Arun Balakumaran, Muhit Ozcan, P. L. Zinzani, Margaret A. Shipp, Gilles Salles, Dzhelil Osmanov, Laura Fogliatto, Jan Walewski, Kamal Bouabdallah, V. Melnichenko, S. Chlosta
Publikováno v:
Hematological Oncology. 35:62-63
Autor:
Marek Trneny, Thierry Lamy, Jan Walewski, Meera Patturajan, Dzhelil Osmanov, Tsvetan Biyukov, Luca Arcaini, Julia Alexeeva, John Radford, David Belada, Wojciech Jurczak, Marie-Laure Casadebaig Bravo, Jiri Mayer
Publikováno v:
Trneny, M, Lamy, T, Walewski, J, Jurczak, W, Belada, D, Mayer, J, Radford, J, Alexeeva, J, Osmanov, D, Biyukov, T, Patturajan, M, Bravo, M-L C & Arcaini, L 2014, ' Phase II randomized, multicenter study of lenalidomide vs best investigator’s choice in relapsed/refractory mantle cell lymphoma : results of the MCL-002 (SPRINT) study ', Blood, vol. 124, no. 21, pp. 626 . https://doi.org/10.1182/blood.V124.21.626.626
ResearcherID
Publons
ResearcherID
Publons
Introduction: Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin’s lymphoma with poor outcome, especially after failure of first-line treatment. Lenalidomide, an immunomodulatory drug with antineoplastic and antiproliferative effects, has show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::743b873745b25206302b6b58866dec99
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000349243507159&KeyUID=WOS:000349243507159
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000349243507159&KeyUID=WOS:000349243507159
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Bertrand Coiffier, Dzhelil Osmanov, Mariana Vasilica, Won Seog Kim, Aliaksandr Prokharau, Sungyoung Lee, Juan-Manuel Sancho, Christian Buske, Jin Seok Kim, Sang-Joon Lee, Wojciech Jurczak, Edvard Javrid, Larry W. Kwak, Rajnish Nagarkar, Jose Angel Hernandez Rivas, Michinori Ogura, Yunju Bae
Publikováno v:
Journal of Clinical Oncology. 35:7532-7532
7532 Background: CT-P10 is a biosimilar candidate to the innovator rituximab (RTX). In patients with rheumatoid arthritis, CT-P10 has demonstrated equivalence in pharmacokinetics (PK) and efficacy (Yoo, ACR 2016). This study aimed to demonstrate non-